T2DM (Type 2 Diabetes Mellitus) Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about T2DM (Type 2 Diabetes Mellitus) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

T2DM (Type 2 Diabetes Mellitus)
Ascletis Pharma (China) Co., Limited100 enrolled8 locationsNCT07321678
Recruiting
Phase 4

GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

T2DM (Type 2 Diabetes Mellitus)
Federico II University80 enrolled2 locationsNCT07314684
Recruiting
Phase 4

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

T2DM (Type 2 Diabetes Mellitus)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.430 enrolled1 locationNCT07244003
Recruiting

Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D

Type 2 Diabetes Mellitus (T2DM)Type 2 DiabetesT2DM+4 more
University of Colorado, Denver36 enrolled1 locationNCT07005362
Recruiting
Not Applicable

Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine

Type 2 DiabetesDiabetes Type 2Nutrition+4 more
University of North Carolina, Chapel Hill60 enrolled1 locationNCT07148713
Recruiting
Not Applicable

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

T2DMT2DM (Type 2 Diabetes Mellitus)Type 2 Diabetic Patients
Beijing Hospital115 enrolled16 locationsNCT03987308
Recruiting
Not Applicable

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

DyslipidemiasT2DM (Type 2 Diabetes Mellitus)
Korea University Anam Hospital3,958 enrolled1 locationNCT06293417
Recruiting
Phase 2

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

MetforminT2DM (Type 2 Diabetes Mellitus)SGLT2-Inhibitors
Shinshu University120 enrolled1 locationNCT05469659